Skip to main content
CSL Behring News)

Global Newsroom

Recent News Releases

 

Latest CSL News

Latest CSL News

University of Oxford/AstraZeneca Vaccine Candidate
08 Nov 2020

CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne.

CSL Named as One of the World’s Best Employers
29 Oct 2020

Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year

CSL’s Global Role in Battling COVID-19
08 Oct 2020

Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19

COVID-19 Update
08 Oct 2020

CSL continues to provide medicines to patients around the world.

Joy Linton named as Chief Financial Officer
01 Oct 2020

CSL has appointed Ms Joy Linton, a well-respected global leader with extensive strategic and financial experience as Chief Financial Officer (CFO.) Ms Linton will be based at CSL’s Head Office in Melbourne and will join CSL’s Global Leadership Group.

CSL Media Statement on COVID19 Vaccine Manufacture
18 Aug 2020

Development of the University of Queensland’s vaccine candidate remains CSL’s priority.

Inaccurate Report of COVID-19 Vaccine Agreement
18 Jul 2020

The report made by the Courier Mail and other media agencies today that an agreement has been struck to specifically secure supply, when a vaccine is available, for Queensland, is incorrect.

Rare Diseases in Asia-Pacific
16 Jul 2020

Economist Intelligence Unit (EIU) Report launched today reveals only one in three rare disease patients receives the best-available, evidence-based care.

Less than a third of surveyed healthcare professionals (HCPs) in Australia encounter a rare disease patient more than once every six months.

Across APAC, 94% of rare conditions have no approved medical treatment, highlighting need to shift towards the provision of non-medical services.

UQ COVID 19 Vaccine to Commence Human Trials
13 Jul 2020

Today, the first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have commenced in Australia

CSL Behring Begins Trial for Respiratory Distress
06 Jul 2020

Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe respiratory distress due to COVID-19 related pneumonia.

CSL Behring now evaluating 5 approaches to preventing and treating COVID-19.

CSL Behring Gene Therapy Agreement with uniQure
24 Jun 2020

Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits with only one dose.

CSL Behring builds on legacy of delivering innovative treatment options for people with Hemophilia B.

CSL Behring to Acquire Biotech Company Vitaeris
08 Jun 2020

Builds on CSL Behring’s promise and commitment to the transplant community.

Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring’s portfolio.

CSL Behring Presents Results for Garadacimab
08 Jun 2020

Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation

2021 CSL Centenary Fellowships
01 Jun 2020

Applications are now open for the 2021 CSL Centenary Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic institute.

Media Contacts

Christina Hickie

CSL Limited
Senior Manager, Communications
Phone: +61 429 609 762

News archive 2016 pdf
News archive 2015 pdf
News archive 2014 pdf
News archive 2013 pdf